Laboratorios Rovi (ROVI) lowers 2026 revenue outlook after Q1 income drop
Laboratorios Rovi has lowered its full-year 2026 revenue outlook after reporting a 1.5% decrease in first-quarter operating income to €152.5 million and a 33% fall in EBITDA to €20.3 million. The Spanish pharmaceutical company now anticipates low to mid-single-digit percentage growth in its 2026 revenues compared to 2025, a reduction from its earlier forecast of high single-digit to low double-digit growth. On Friday, 15 May 2026, Rovi shares are trading at €59.05, down 0.6% in the session.
The deterioration in quarterly performance is primarily attributed to a deceleration within its heparin division, compounded by an increase in operating expenses. These factors have prompted the company to adjust its expectations for the year, indicating a more challenging operating environment than initially anticipated and directly impacting Rovi's financial projections.
This guidance adjustment follows a period of sustained pressure on the company's valuation. On Wednesday, 13 May, Laboratorios Rovi's shares fell 2.0% following news of a 48% reduction in its net profit and an earlier forecast adjustment. The current trading price of €59.05 reflects a continuation of the downward trend observed throughout the week, with the stock descending from its previous close of €59.40.
What a Change in Rovi's Revenue Outlook Means for Its Stock
Laboratorios Rovi is a Spanish pharmaceutical firm focused on developing, manufacturing, and bringing a variety of medicines to market. Their business model revolves around researching and producing drugs, notably within their heparin division, which they then sell and distribute to hospitals, pharmacies, and other healthcare providers, generating revenue from these sales.
The primary driver behind today's share price movement is the company's decision to lower its revenue growth forecasts for the full year 2026. Rovi now anticipates its revenues will grow by a low-to-mid single-digit percentage, a significant reduction from its earlier projection of high-single-digit to low-double-digit growth. This adjustment follows a first quarter where operating revenues fell by 1.5% to €152.5 million, and earnings before interest, taxes, depreciation, and amortisation (EBITDA) dropped by 33% to €20.3 million, largely due to a slowdown in its heparin division and rising operational costs.
This downward revision of future expectations has led to Laboratorios Rovi's shares trading down 0.6% today, 15 May 2026, at €59.05, compared to yesterday's closing price of €59.40.
Consider a well-regarded software company that consistently releases popular updates, leading analysts to expect strong subscription growth for the year. If that company suddenly announces it now expects significantly fewer new subscribers than initially promised, even if its existing products are still performing, investors will adjust their valuation of the company's shares downwards because the outlook for future earnings has diminished.
![Laboratorios Rovi[es] logo](https://images.financialmodelingprep.com/symbol/ROVI.MC.png)
Laboratorios Rovi[es]
Laboratorios Farmaceuticos Rovi, S.A. (ROVI) is a Spanish pharmaceutical firm engaged in the research, development, production, and commercialisation of a diverse range of pharmaceutical products. Its portfolio includes treatments for venous thromboembolic disease (Hibor, Becat), heart failure (Neparvis), hypercholesterolemia (Absorcol, Vytorin, Orvatez), chronic obstructive pulmonary diseases (Hirobriz Breezhaler, Ulunar Breezhaler), benign prostatic hyperplasia (Volutsa), and ADHD (Medikinet, Medicebrán). ROVI also markets hospital products for imaging diagnostics, such as contrast agents (Iomeron, Iopamiro, Multihance, Prohance, Sonovue) and contrast injection systems. Beyond its proprietary offerings, the company provides contract manufacturing services for various pharmaceutical forms and distributes licensed products from other laboratories. ROVI serves a broad client base including wholesalers, medical professionals, and patients across Spain, the European Union, OECD countries, and internationally. Founded in 1946, it is headquartered in Madrid, Spain.